All-cause mortality risk in patients with type 1 diabetes and more than one microvascular complication does not exceed the combined risk estimates of each separate complication, Danish researchers report.
The results of two individual patient data meta-analyses support albuminuria as a surrogate marker of treatment response in patients with chronic kidney disease, particularly those with high baseline albuminuria.
The risk for end-stage renal disease is high among patients with type 1 diabetes and advanced nephropathy but varies by country, shows an analysis of cohorts from Finland, France, Denmark, and the USA.
The presence of mild-to-moderate anemia or chronic kidney disease does not have a clinically significant effect on the interpretation of glycated hemoglobin as a marker of glycemic control, Danish research shows.
Results of AdDIT show that treatment with an ACE inhibitor, a statin, or both does not protect against the increased albumin excretion that frequently occurs in patients with type 1 diabetes during adolescence.